Balancing expectations: An unmet need in the orphan disease arenaThere are between 6000 and 8000 rare diseases in the world, and one in ten people in Europe Share XBalancing expectations: An unmet need in the orphan disease arenahttps://pharmaphorum.com/views-analysis-market-access/balancing-expectations-rare-disease-arena/
Collaboration can ensure access to life-changing innovationAs a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new Share XCollaboration can ensure access to life-changing innovationhttps://pharmaphorum.com/views-analysis-market-access/access-life-changing-innovation-risk-sharing-scheme/
A payer’s perspective on value-based contracting (VBC)What payer wouldn’t want to ensure that they pay for value when buying drugs? If the emerging trend Share XA payer’s perspective on value-based contracting (VBC)https://pharmaphorum.com/views-analysis-market-access/payers-perspective-value-based-contracting-vbc/
Paying for value: US state of playDrug pricing in the US is a perennial topic, which is no surprise given the the US spends Share XPaying for value: US state of playhttps://pharmaphorum.com/views-analysis-market-access/us-value-based-payment-models/
When knowledge drives results: the impact of a winning data strategyHaving an effective clinical trial data strategy in place can make the difference between success and an expensive Share XWhen knowledge drives results: the impact of a winning data strategyhttps://pharmaphorum.com/r-d/views-analysis-r-d/when-knowledge-drives-results-the-impact-of-a-winning-data-strategy/
UK’s drug supply contingency plan for hard BrexitThe UK government has issued several documents to help businesses in planning for the eventuality of a no-deal Share XUK’s drug supply contingency plan for hard Brexithttps://pharmaphorum.com/views-analysis-market-access/hard-brexit-uk-drug-supply-contingency-plan/
Value-based healthcare: What’s it worth to you?It takes healthy people to make a healthy society – and that must be taken into account when Share XValue-based healthcare: What’s it worth to you?https://pharmaphorum.com/views-and-analysis/value-based-healthcare-whats-worth/
Brexit from the inside: MP’s views on how it will impact pharmaWith the potential for a hard-no-deal Brexit becoming closer to reality with each passing day, the question of Share XBrexit from the inside: MP’s views on how it will impact pharmahttps://pharmaphorum.com/views-and-analysis/brexit-inside-mps-views-impact-pharma/
Division on European HTAThere have been aspirations for closer collaboration between European Union (EU) Member States (MS) on Health Technology Assessment Share XDivision on European HTAhttps://pharmaphorum.com/views-and-analysis/hta-european-health-technology-assessment-division-progress/
